Activation of Peroxisome Proliferator-Activated Receptor δ Stimulates the Proliferation of Human Breast and Prostate Cancer Cell Lines
- 1 May 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 64 (9) , 3162-3170
- https://doi.org/10.1158/0008-5472.can-03-2760
Abstract
The nuclear receptor peroxisome proliferator-activated receptor δ [PPARδ/β (NR1C2)] has been implicated in colorectal carcinogenesis by various molecular genetic observations. These observations have recently been supported by studies of activation of PPARδ by pharmacological agents. Here we present the first report of the stimulation of breast and prostate cancer cell growth using PPARδ selective agonists. Activation of PPARδ with compound F stimulated proliferation in breast (T47D, MCF7) and prostate (LNCaP, PNT1A) cell lines, which are responsive to sex hormones. Conversely, we have found that several steroid-independent cell lines, including colon lines, were unresponsive to compound F. These findings were confirmed with an additional high-affinity PPARδ agonist, GW501516. Conditional expression of PPARδ in MCF7 Tet-On cells resulted in a doxycycline-enhanced response to GW501516, thus providing direct genetic evidence for the role of PPARδ in the proliferative response to this drug. Activation of PPARδ in T47D cells resulted in increased expression of the proliferation marker Cdk2 and also vascular endothelial growth factor α (VEGFα) and its receptor, FLT-1, thus, suggesting that PPARδ may initiate an autocrine loop for cellular proliferation and possibly angiogenesis. Consistent with this hypothesis, we demonstrated a pro-proliferative effect of GW501516 on human umbilical vein endothelial cell cultures and found that GW501516 also regulated the expression of VEGFα and FLT-1 in these cells. Our observations provide the first evidence that activation of PPARδ can result in increased growth in breast and prostate cancer cell lines and primary endothelial cells and supports the possibility that PPARδ antagonists may be of therapeutic value in the treatment of breast and prostate cancer.Keywords
This publication has 36 references indexed in Scilit:
- A Short and Efficient Synthesis of the Pharmacological Research Tool GW501516 for the Peroxisome Proliferator-Activated Receptor δThe Journal of Organic Chemistry, 2003
- PPARδ activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cellsBiochemical and Biophysical Research Communications, 2003
- Differential Regulation of Vascular Endothelial Growth Factor Expression by Peroxisome Proliferator-activated Receptors in Bladder Cancer CellsJournal of Biological Chemistry, 2002
- Critical roles of PPARβ/δ in keratinocyte response to inflammationGenes & Development, 2001
- Impaired skin wound healing in peroxisome proliferator–activated receptor (PPAR)α and PPARβ mutant miceThe Journal of cell biology, 2001
- Prostaglandins Up-Regulate Vascular Endothelial Growth Factor Production through Distinct Pathways in Differentiated U937 CellsBiochemical and Biophysical Research Communications, 2000
- Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancerOncogene, 2000
- AP-2 transcription factors in the regulation of ERBB2 gene transcription by oestrogenOncogene, 2000
- The biological action of cDNAs from mutated estrogen receptors transfected into breast cancer cellsCancer Letters, 1995
- Stimulation of prostacyclin biosynthetic activity by estradiol in rat aortic smooth muscle cells in cultureBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1980